AINE y riesgo cardiovascular

[1]  T. Gill,et al.  Cause for concern in the use of non-steroidal anti-inflammatory medications in the community -a population-based study , 2011, BMC family practice.

[2]  K. Rothman,et al.  Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study , 2011, BMJ : British Medical Journal.

[3]  Bruce Guthrie,et al.  High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice , 2011, BMJ : British Medical Journal.

[4]  L. Køber,et al.  Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction: A Nationwide Cohort Study , 2011, Circulation.

[5]  M. Egger,et al.  Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis , 2011, BMJ : British Medical Journal.

[6]  Á. Mészáros,et al.  Trends in the non‐steroidal anti‐inflammatory drug market in six Central–Eastern European countries based on retail information , 2010, Pharmacoepidemiology and drug safety.

[7]  T. Macdonald,et al.  Effect of ibuprofen on cardioprotective effect of aspirin , 2003, The Lancet.

[8]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[9]  G. Singh,et al.  Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. , 1998, The American journal of medicine.